SB-007 addresses the root cause of Stargardt disease with the potential to treat all patients across all ABCA4 mutations SB-007 is the first dual AAV gene therapy in clinical development for Stargardt disease BARCELONA, SPAIN, 13 March 2025 – SpliceBio, a clinical-stage genetic medicines company pioneering Protein Splicing to address diseases caused by mutations in […]
BARCELONA, 10 April 2024 – SpliceBio, a genetic medicines company harnessing Protein Splicing to develop the next generation of gene therapies, is pleased to announce that its management team will be attending and presenting at key scientific and investor conferences in April to June 2024. Read more…
SpliceBio is eligible to receive upfront, opt-in and milestone payments up to $216 million plus royalties Spark secures exclusive worldwide rights to SpliceBio’s proprietary Protein Splicing platform to develop, manufacture and commercialize a gene therapy targeting an undisclosed retinal disease BARCELONA, October 17th, 2023 – SpliceBio, a genetic medicines company harnessing Protein Splicing to develop the […]
Financing co-led by UCB Ventures and Ysios Capital with participation by New Enterprise Associates, Gilde Healthcare, Novartis Venture Fund and Asabys Partners Unique Protein Splicing platform enables efficient delivery of large genes with adeno- associated vectors (AAV) Proceeds will be used to advance the lead program in Stargardt disease into the clinic and expand pipeline […]
